Facilitator, direct or hybrid: how demand should reach you
Facilitator versus direct is a channel design question, not a moral one. Intermediaries buy reach and speed in markets where you have no presence. Direct demand buys the relationship, the data and control of the price story, but compounds slowly. Most groups end up hybrid. The difference between a good hybrid and a bad one is whether anyone chose it, market by market.
Every hospital group with an international programme eventually has the same argument in the same meeting. One side says the facilitators bring the cases and without them the beds sit empty. The other side says the hospital is paying for demand it could own, and that the family never really becomes ours. Both sides are usually right about their own evidence and wrong about the conclusion.
The question of facilitator versus direct is not a moral one and it is not a single decision. It is a channel design question, and the sensible answer almost always differs by market, by specialty and by the stage your programme is at. Getting it wrong is expensive in a particular way: you do not lose money quickly, you lose the ability to know anything about your own demand.
This article sits in a series on medical value travel and assumes the groundwork in what this business actually is and who the patient is. It is written for the person who has to choose the model and then defend it.
The three ways international demand reaches an Indian hospital
Strip away the variations and there are three routes.
In the facilitated route, an intermediary finds the patient, assembles the file, collects options from several hospitals, presents them to the family, and often accompanies the case through arrival and stay. The hospital receives a packaged case and pays for it in some form.
In the direct route, the family finds the hospital themselves, usually through search, social, video, an AI assistant’s answer, a returning patient or a doctor abroad who refers to you by name. They write to your desk and the relationship is yours from the first message.
In the referred route, which sits between the two, a doctor, employer, community body or sponsor abroad points the family towards you without acting as a commercial intermediary. This route behaves much more like direct demand, but it is built through relationships rather than through content.
Most groups have all three and manage only one of them deliberately. Worse, many cannot tell which route a given arrival came through, because the field that would record it either does not exist or is filled in at billing by someone guessing. That single gap makes the whole argument unresolvable, since each side is describing a different set of cases from memory.
Facilitator versus direct: what each one actually buys you
A facilitator buys you reach, speed and case assembly in a market where you have no presence. The demand exists today rather than next year. Somebody already knows how families in that town make decisions, which documents take time, and who in the family needs convincing. You are renting local knowledge you do not have.
Direct demand buys you the relationship, the data, control of what the family is told about price, and a cost structure that improves as the asset matures rather than one that scales with volume. It also buys you something less obvious: the ability to see your own market clearly, because every enquiry carries a country, a city, a language and a specialty that you recorded yourself.
The trade is really between time and control. Facilitated demand is faster and less controllable. Direct demand is slower and compounds. A programme that needs volume this year and a programme that needs a durable position in three years are not making the same choice, and pretending otherwise is how these meetings go in circles.
What a facilitator does that hospitals underrate
Hospital teams tend to describe facilitators as middlemen who mark up a case. That description misses most of the work and leads to bad negotiation.
The useful ones do things a hospital genuinely cannot do from India. They sit in the source market and meet families in person, which matters enormously when the family is deciding whether any of this is real. They collect and translate records into something a consultant can read. They manage the gap between a medical opinion and a family raising money. They handle the practical side of travel, arrival and sometimes accommodation. They absorb the emotional labour of a decision that takes months. And they carry the risk of cases that never travel, which for a hospital is invisible and for them is their entire cost base.
When a hospital treats that as pure margin extraction, it negotiates on price alone, the good partners walk away, and what remains are the ones competing on discount. That is how a market degrades.
There is a quality spread among partners that matters more than the commercial terms. Some assemble complete files, set honest expectations and prepare families properly for what a hospital stay in another country involves. Others forward a photograph of a prescription and a phone number. The second kind generates work for your desk, disappointed families and eventually complaints that attach to your name rather than theirs. Judging partners on the quality of the cases they send, rather than on volume alone, is the single most useful discipline in managing them.
What you give up when someone else owns the relationship
The costs are real too, and they are mostly informational.
You do not know who the patient is until they are nearly here. You do not know how many families considered you and chose elsewhere. You cannot see which city they came from, what language they use, or what they searched before anyone spoke to them. Your reporting shows arrivals, which is the one number that cannot tell you anything about demand.
You also lose control of the story, particularly about price. If a partner presents a figure the family understands as final and your estimate later includes items they were never told about, the family experiences that as a hospital cheating them. They will not blame the intermediary. This is why estimate discipline has to travel with the case regardless of channel, which the series covers in the estimate that survives arrival.
Follow-up suffers too. If the ongoing relationship with the family belongs to an intermediary, the hospital rarely hears how the patient is doing, rarely receives the second case from the same family, and rarely learns why a market went quiet. The feedback loop that would tell you what to fix runs through someone whose interest is not identical to yours.
The third cost is strategic. A programme whose entire flow arrives through two or three partners has a concentration risk that nobody has written down. If one of them moves their volume elsewhere, the quarter disappears and there is no asset left behind.
Building direct demand takes longer than anyone budgets
Direct international demand is built from content in the right languages, presence in search and video where families actually look, a desk that answers well, referring doctors abroad who know your consultants by name, and former patients who speak well of you at home.
All of those compound, and none of them arrives in a quarter. This is the part that gets underestimated in board discussions. A hospital that decides to go direct and expects the mix to shift within two quarters will conclude that direct does not work, usually just before it starts working.
The relationship side deserves particular patience. A doctor abroad who refers one case and sees it handled beautifully will refer more, and that stream is more durable than anything you buy. Building it deliberately is a long programme of its own, covered in the referring doctor abroad.
My own position, after watching several of these: build direct demand in the markets where you already have arrivals, not in the markets you wish you had. Existing patients are the cheapest proof you will ever get.
It also helps to be realistic about what direct means in practice. Very few international families go from a search result to a booking without speaking to a human being, so direct does not mean automated. It means the human being they speak to works for you, which changes what they are told, what is recorded and who they come back to next time.
The hybrid most groups end up with, and how to design it on purpose
Almost everyone lands on a mix. The difference between a good mix and a bad one is whether anybody chose it.
A designed hybrid looks like this. Certain markets are served primarily through partners because you have no presence, no language cover and no realistic route to either. Certain markets are served directly because you already receive enquiries, you can answer in the language and you have returning families. A small number are transitional: partner-led today, with a deliberate investment in content, language and referring doctors so the mix shifts over a stated period.
The rules that make it work are unglamorous. One estimate format used for every channel, so a family never gets two different answers about the same treatment. One service standard, so a partner-referred family is not treated worse or better than a direct one. Clear attribution rules agreed in advance, because the fight over who owns a case that was referred by a partner and then enquired directly will otherwise happen once a quarter forever. And a written statement of which markets are which, reviewed annually.
Getting the market classification right depends on seeing your own demand honestly, which is a discipline in itself and is set out in reading international demand from data rather than anecdotes.
Contracting, consent and the data question
Three things belong in any arrangement with a partner, and most hospital agreements address only the first.
Commercial terms, obviously: what is paid, for what, when, and what happens if a case is cancelled or a patient does not travel. Beyond that, service obligations in both directions: what the partner will represent about the hospital, what they will never say, what the hospital commits to in response time and documentation, and who handles a complaint.
Then data and consent, which is where most arrangements are weakest. Patient information arrives from a third party in another country and becomes yours to hold. Under India’s data protection regime you need a defensible answer about how that information was collected, what the family consented to, what you do with it and how long you keep it. Health data deserves the strictest handling you have regardless of the patient’s nationality. A partner forwarding reports on a personal messaging account is not a chain of custody anybody can defend.
There is a marketing consent question inside this too. A family whose details reached you through an intermediary has not necessarily agreed to hear from your hospital again, and treating that list as a marketing database is a mistake that is easy to make and hard to undo.
Deciding market by market, not once for everything
The practical method is to score each source market on four things you already know or can find out quickly.
Do you already receive direct enquiries from there. Can you answer in the language that market uses, today. Do you have returning patients or a referring doctor with a relationship. And is the route to the patient short enough that content and search can reach them, or is the decision made almost entirely in person?
Markets that score well on the first three are direct candidates, and partners there should be a supplement rather than the channel. Markets that score poorly on all four are partner markets, and should be run as such without apology or pretence. The interesting ones are in between, and those are where a stated transition plan earns its place.
Whatever the model, the family still judges you on how you answered, which is why the first reply matters just as much for a partner-referred case as for a direct one.
A first quarter that makes the choice easier
If this argument is live in your organisation, do not settle it with opinions. Settle it with a season of evidence.
Classify every arrival from the last year by route: partner, direct or referred. Most groups cannot do this at all, and finding that out is itself the finding. Then list your source markets and score them on the four questions above. Then pick one market where you already have direct enquiries and invest properly in it for a quarter: language cover, content, a named coordinator, a referring doctor relationship. Leave the partner markets alone during that quarter so you are not confusing yourself.
At the end of it you will have a real answer for your own hospital rather than a borrowed one. And you will have the thing that makes every later decision easier: a view of your own demand that does not depend on anybody else telling you about it.
Questions people ask
It describes how international demand arrives. In the facilitated route an intermediary finds the family, assembles the file, presents options and often accompanies the case, and the hospital pays for that in some form. In the direct route the family finds the hospital themselves through search, content, a returning patient or a referring doctor, and the relationship belongs to the hospital from the first message onwards.
Neither, in the abstract. Facilitated demand is faster and less controllable. Direct demand is slower to build and compounds over time. The right answer differs by source market, by specialty and by how mature your programme is. The mistake is choosing once for everything, or drifting into a mix that nobody designed and nobody can defend when asked why it looks the way it does.
Concentration and blindness. If most arrivals come through a small number of intermediaries, one of them moving volume elsewhere removes a quarter with no asset left behind. You also cannot see your own market, because you only meet families who already chose you. Reporting shows arrivals, which says nothing about how many families considered you and went somewhere else.
Total cost of a partner-sourced case including service obligations, not just the headline commercial term. Cancellation and non-arrival treatment. Whether estimates issued through partners match estimates issued directly, since inconsistency shows up later as disputes and write-offs. And the trend in channel mix over time, because a mix drifting towards partners without a decision having been made is a quiet strategic shift.
Because most of the work is invisible from India. Meeting families in person, translating records, managing the months between a medical opinion and money being raised, handling travel and arrival, and carrying the cost of every case that never travels. Treating that as margin extraction leads to negotiating on price alone, which drives away the capable partners and leaves the ones competing on discount.
Use one estimate format for every channel, with stated inclusions, exclusions and revision conditions, and make it the only document that quotes. Put what a partner may and may not represent into the agreement explicitly. Then check, by asking arriving families what they were told before they travelled. Families do not blame intermediaries for a surprise at billing. They blame the hospital.
Longer than most plans assume. Content in the right languages, visibility in search and video, a desk that answers well, referring doctors abroad and returning patients all compound rather than switch on. A programme expecting the channel mix to move within two quarters will usually abandon the effort shortly before it starts working. Treat it as a multi-year asset with quarterly evidence of progress.
Mainly that case quality and file completeness differ by route, and that expectations may have been set by someone outside the hospital. Partner-referred cases sometimes arrive with promises the clinical team never made. A single service standard, a single estimate and a clear rule that only clinicians give clinical views protects consultants from inheriting a conversation they were not part of.
Service obligations in both directions, including response times, documentation and complaint handling. What the partner may represent about the hospital and what they may never say. Attribution rules for cases that come through more than one route. And a proper answer on data: how patient information was collected, what the family consented to, how it reaches you and how long you keep it.
Patient information arriving from a third party abroad becomes yours to hold and account for. You need a defensible view of how it was collected and what the family agreed to. Health information deserves your strictest handling whatever the patient’s nationality. Records forwarded through personal messaging accounts are not a chain of custody anyone can defend, and a partner-sourced list is not a marketing database.
Score it on four things. Do you already receive direct enquiries from there. Can you answer in that language today. Do you have returning patients or a referring doctor relationship. And can content and search realistically reach the family, or is the decision made almost entirely in person. Strong on the first three means direct. Weak on all four means partner led.
Yes, but state it as a transition with a timeframe rather than switching abruptly. Invest in language cover, content and referring doctor relationships in that market while the partner flow continues. Expect the shift to take longer than a year. Ending a partner relationship before the direct capability exists usually produces a gap that is harder to recover than the original dependency.
A few weeks of honest work. Classify last year’s arrivals by route, which most groups cannot currently do, and score your source markets on the four questions. That alone resolves most of the internal argument, because it replaces opinions with a picture of your own demand. Choosing one market to serve directly for a quarter gives you the rest of the answer.
Letting the mix happen instead of choosing it, then discovering the concentration only when a partner reduces volume. The second most common is negotiating partners down on price until only the weakest remain, which degrades the experience for families and eventually the hospital’s name in that market. Both are avoidable with a written channel decision reviewed once a year.
